ReviewImmunotherapy2020
The immunotherapy revolution in genitourinary malignancies.
Review in Immunotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Bioinformatics analysis and experimental validation confirm COL6A3 as a promising target for renal cell carcinoma therapy.Translational andrology and urology · 2026Article
- MicroRNAs and immunotherapy in testicular germ cell tumors: opportunities and challenges for modulation of the immune microenvironment.Frontiers in immunology · 2026Review
- Prognostic Significance of CD11b-, CD8-, and CD163-Positive Tumor-Infiltrating Immune Cells in Distal Bile Duct Cancer.Journal of personalized medicine · 2024Article
- Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Immunotherapy in the Treatment of Localized Genitourinary Cancers.JAMA oncology · 2023Article
- MTHFD2 promotes PD-L1 expression via activation of the JAK/STAT signalling pathway in bladder cancer.Journal of cellular and molecular medicine · 2023Article
- CHMP4C as a novel marker regulates prostate cancer progression through cycle pathways and contributes to immunotherapy.Frontiers in oncology · 2023Article
- Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.Nature medicine · 2021Article
- CALD1 promotes the expression of PD-L1 in bladder cancer via the JAK/STAT signaling pathway.Annals of translational medicine · 2021Article
- The emerging role of checkpoint inhibitors for rare genitourinary cancers.Nature reviews. Urology · 2021Article
- GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak.Therapeutic advances in urologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Immune checkpoint inhibitor (ICI) therapy and therapeutic cancer vaccines have continued to demonstrate survival benefit and durable clinical response in patients with renal cell cancer, prostate cancer and bladder cancer, with limited responses in testicular cancer. The role of immunotherapy in combination with chemotherapy or other targeted therapies in the neo-adjuvant, adjuvant and metastatic setting is actively being explored. We describe the current immunotherapy-related treatment modalities approved for genitourinary cancers, focusing on immune checkpoint inhibitors, vaccines and other modalities, and highlight ongoing studies involving immunotherapy in these cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.